Windlas Biotech Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Windlas Biotech is trading at Rs 840.15 with near-term consolidation expected , the 2027 target of Rs 755 is approximately 10 percent below the current price. The more compelling case is in the outer years , Rs 835 by 2028 and Rs 1,010 by 2030 , as the earnings model builds toward that trajectory. Valued at roughly 22x FY26 EPS (₹31.3), with earnings expected to compound near 10% annually before slowing to approximately8%.

This article breaks down the Windlas Biotech share price target for 2027, 2028, and 2030, the sector-specific drivers behind the analyst model, and the risks that could delay or derail the forecast.

Click Here – Get Free Investment Predictions

Windlas Biotech Company Overview and Share Price Target Summary

Metric	Details
NSE Ticker	WINDLAS
Sector	IT and Technology
CMP (14 Aug 2026)	Rs 840.15
Market Cap	Rs 1762 Cr
Windlas Biotech Share Price Target 2027	Rs 755 (-10%)
Windlas Biotech Share Price Target 2028	Rs 835 (-1%)
Windlas Biotech Share Price Target 2030	Rs 1,010 (+20%)
Bull Case 2030	Rs 1,293
Bear Case 2030	Rs 758

Key context: Valued at roughly 22x FY26 EPS (₹31.3), with earnings expected to compound near 10% annually before slowing to approximately8%.

Valued at roughly 22x FY26 EPS (₹31.3), with earnings expected to compound near 10% annually before slowing to approximately8%..

Why Analysts Have Set the Windlas Biotech share price target at Rs 755 for 2027

Deal Wins and Renewals Provide Multi-Quarter Revenue Visibility

This is the clearest reason the analyst model converges on Rs 1,010 by 2030. Valued at roughly 22x FY26 EPS (₹31.3), with earnings expected to compound near 10% annually before slowing to approxima. Tracking this factor quarterly gives the earliest signal on whether the long-term analyst target stays on course.

AI-Driven Demand Is Opening New Revenue Pools

The Windlas Biotech share price target for 2028 , Rs 835 , is built partly on this continuing to hold. If it deteriorates, the timeline for the outer-year forecast extends, not the target itself. Investors should track it with every results cycle.

Margins Are Holding Despite Wage Inflation Headwinds

This underpins Windlas Biotech's growth beyond the 2027 near-term. It is the kind of durable structural factor that keeps analysts positive on the 2030 target even when quarterly numbers disappoint.

Client Mix Is Shifting Toward Higher-Value Engagements

For the 2028 recovery thesis to work, Windlas Biotech needs to maintain consistency here. One cycle of weakness would not break the long-term case, but two consecutive quarters of deterioration would prompt downgrades.

India's IT Export Story Remains a Multi-Year Structural Theme

This is the macro layer that most company-specific screens miss. It amplifies Windlas Biotech's own earnings compounding and is why analysts are more constructive on the 2030 horizon than on 2027.

Windlas Biotech Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown

2027 Target: Rs 755

Rs 755 is the 2027 analyst target, implying near-term consolidation expected , the 2027 target of Rs 755 is approximately 10 percent below the current price. At this level, Windlas Biotech would be trading on forward multiples consistent with the current earnings trajectory. The 2027 milestone is essentially a staging post , confirmed only after two to three quarters of on-track delivery.

2028 Target: Rs 835

Rs 835 is where analysts see Windlas Biotech by 2028, roughly -1 percent above today's price. By FY29, the business should have moved past the near-term consolidation, and the Windlas Biotech share price target for 2028 typically re-rates faster than markets initially expect once the earnings inflection becomes visible.

2030 Target: Rs 1,010

The long-term case is Rs 1,010 by 2030 , a potential gain of approximately 20 percent from CMP Rs 840.15, which works out to a 4-year CAGR of roughly 5 percent. By FY31, Windlas Biotech should be operating at a scale and earnings quality that justifies the multiple implied by this target. Please verify all data at NSE and BSE before making any investment decision.

Bull Case and Bear Case for Windlas Biotech by 2030

Bull Case: Rs 1,293

The bull case lands at Rs 1,293 by 2030. This requires better-than-expected earnings growth alongside a re-rating of the multiple , both need to land together. Favourable macro conditions, new business wins, or a sector re-rating could drive this scenario without needing extraordinary operational delivery from the company.

Bear Case: Rs 758

The bear case is Rs 758 by 2030 , still above today's price in most scenarios, but a significantly slower path. This applies if earnings miss across FY27 to FY28, competitive pressure intensifies, or a macro slowdown compresses sector multiples before Windlas Biotech can re-rate upward.

Scenario	Target 2030	Return	Key Assumption
Bull Case	Rs 1,293	+54%	Above-consensus growth; multiple expansion
Base Case	Rs 1,010	+20%	Base-case CAGR; peer multiples hold
Bear Case	Rs 758	-10%	Earnings miss; macro pressure; multiple contraction

Key Risks to the Windlas Biotech Forecast

Earnings Deceleration

Any quarter where Windlas Biotech's growth falls below expectations is likely to trigger a PE de-rating, not just an EPS miss, compounding the price impact.

Sector Headwinds

Policy changes, commodity cycles, or demand slowdowns specific to Windlas Biotech's sector could reduce visibility on the targets beyond 12 months.

Competitive Disruption

New entrants or pricing aggression from existing competitors can erode the market share assumptions built into the analyst model.

Macro Risks

A broader economic slowdown affecting consumer or corporate spending would compress multiples across the board, regardless of company-specific delivery.

How to Invest in Windlas Biotech

Start by tracking Windlas Biotech's quarterly results against the model assumptions. The Univest Screener gives you live fundamentals, analyst upgrade history, and price alerts on NSE ticker WINDLAS , the same data points that drive the Windlas Biotech share price target model. Build positions in tranches across the 2027 to 2028 window rather than committing fully now, and consult a SEBI-registered financial advisor before investing.

Track This Stock Live on the Univest Screener

Conclusion

The Windlas Biotech share price target of Rs 755 for 2027, Rs 835 for 2028, and Rs 1,010 for 2030 reflects the analyst model built on Windlas Biotech's earnings trajectory in the it and technology sector. The near-term picture is one of consolidation; the case for patient investors is in the 2028 to 2030 window. Always verify financial data at NSE India and BSE India before making any investment decision.

Download the Univest iOS App or Univest Android App to track Windlas Biotech share price live and get daily stock recommendations.

Frequently Asked Questions on Windlas Biotech Share Price Target 2027 2028 and 2030

What is the Windlas Biotech share price target for 2027?

Ans. The Windlas Biotech share price target for 2027 is Rs 755, which is approximately 10 percent slightly below the current market price of Rs 840.15. This near-term target reflects the analyst consensus as of August 2026. Verify all data at NSE India before investing.

What is the Windlas Biotech share price target for 2030?

Ans. The 2030 analyst target for Windlas Biotech is Rs 1,010, implying approximately 20 percent potential upside from CMP Rs 840.15. This is the base-case extrapolation from the current earnings growth model. These are analyst estimates and not guaranteed returns.

What is the Windlas Biotech share price target for 2028?

Ans. The Windlas Biotech share price target for 2028 is Rs 835, approximately -1 percent from the current price. By FY29, the business should be past the near-term consolidation phase, which makes the 2028 target more realistically achievable than the 2027 level.

Is Windlas Biotech a good long-term investment?

Ans. Windlas Biotech has a defined earnings growth thesis in the it and technology sector, with targets that project meaningful upside by 2030. Whether it suits your portfolio depends on your risk appetite, investment horizon, and current allocation. Speak with a SEBI-registered financial advisor before deciding.

What are the key risks to the Windlas Biotech analyst forecast?

Ans. The most significant risks are earnings deceleration and sector headwinds. Beyond these, broader macro slowdowns and sector-specific headwinds can compress multiples even when the company itself is executing well.

What is the bull case for Windlas Biotech by 2030?

Ans. The bull case target is Rs 1,293 by 2030. This requires above-consensus earnings growth and a re-rating of the PE multiple , both need to happen together. These are analyst projections, not guaranteed outcomes.

What sector does Windlas Biotech belong to?

Ans. Windlas Biotech operates in the it and technology sector. This sector classification influences the peer multiples applied in the analyst target model and the macro factors that most directly affect the company's earnings outlook.

How can I track and invest in Windlas Biotech?

Ans. You can buy Windlas Biotech shares through any SEBI-registered broker using NSE ticker WINDLAS. The Univest Screener lets you track live fundamentals, set price alerts, and monitor analyst ratings. Always consult a SEBI-registered financial advisor before investing.